MSD Makes Undisclosed Equity Investment in Cancer Diagnostics Firm DELFI Diagnostics
Merck, Sharp & Dohme (MSD; NYSE: MRK) has announced an equity investment into DELFI Diagnostics,...
GSK Finalizes Acquisition of Oligonucleotide Specialist Elsie Biotechnologies for Up to $50 Million
GlaxoSmithKline (GSK; NYSE: GSK), a leading UK pharmaceutical company, has announced the completion of the...
Four More Chinese Provinces Include ART in Medical Insurance Payment System
The provincial governments of Jiangxi, Shanghai, Qinghai, and Zhejiang have added assisted reproductive technology (ART)...
J&J Loses US Court Case Over Asbestos in Cosmetic Products; Ordered to Pay $260 Million
Johnson & Johnson (J&J; NYSE: JNJ) suffered a defeat in a US court this week,...
MSD China’s Vaccine Head Tang Xiaochun Departs; HutchMed Welcomes MSD’s Yuan Zezhi as Executive Vice-President
Merck, Sharp & Dohme (MSD; NYSE: MRK) has announced that Tang Xiaochun, who served as...
China Unveils Ambitious 2024 Medical Reforms with Increased Investment and Policy Reforms
The State Council has issued a notification outlining key medical system reforms for 2024, aiming...
Sinovac Biotech Commits USD 100 Million Investment in Brazil for Vaccine Research and Collaboration
Sinovac Biotech Ltd. (NASDAQ: SVA), a leading vaccine specialist based in China, is reportedly set...
Sansure Biotech’s HBV RNA Detection Kit Receives NMPA Marketing Approval
Sansure Biotech Inc., (SHA: 688289), a leading molecular diagnostics company based in China, has announced...
MicroPort Endovascular MedTech Secures NMPA Approval for Vena Cava Filter
Shanghai MicroPort Endovascular MedTech Co., Ltd (SHA: 688016), a prominent medical device company based in...
Qilu Pharmaceutical’s Generic Pomalidomide Wins NMPA Nod for Multiple Myeloma Treatment
Qilu Pharmaceutical, a leading pharmaceutical company based in China, has received approval from the National...
Fosun Pharma’s FCN-159 Receives Priority Review Status from NMPA for Pediatric Neurofibromatosis
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has announced that the National...
Luye Pharma Submits Market Approval Application for Rivastigmine Patch in Japan
Luye Pharma Group (HKG: 2186), a leading pharmaceutical company based in China, has announced a...
HutchMed Initiates Phase I Clinical Trial for HMPL-506 in Hematologic Malignancies
HutchMed (HKG: 0013, NASDAQ: HCM) has announced the commencement of a Phase I clinical study...
Alphamab Oncology Partners with ArriVent BioPharma for Global ADC Development and Commercialization
Alphamab Oncology (HKG: 9966), a biopharmaceutical company based in China, has entered into a research...
Sino Biopharmaceutical Presents FS222 Phase I Results at ASCO Annual Meeting
Sino Biopharmaceutical Ltd (HKG: 1177), a prominent biopharmaceutical company in China, has presented updates from...
Jiangsu Hengrui’s HER2 Targeted ADC SHR-A1811 Poised to Earn Breakthrough Designation in China
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading pharmaceutical company in China, has announced...
3SBio Secures Exclusive Licensing Agreement for Seven Drug Candidates from Subsidiary
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd, a subsidiary of 3SBio Inc. (HKG: 1530), has disclosed...
Rightongene Bio Receives NMPA Approval for BCR-ABL P210 Fusion Gene Detection Kit
Shanghai Rightongene Biotechnology Co., Ltd (SHA: 688217), a biopharmaceutical company based in China, has announced...
WuXi Biologics Expands Manufacturing Capacity with New Bioreactors at Hangzhou Facility
WuXi Biologics (HKG: 2269), a leading Contract Research, Development, and Manufacturing Organization (CRDMO) based in...
J&J’s Tecvayli Shows Promising Response Rates in Multiple Myeloma Trial
Johnson & Johnson (J&J; NYSE: JNJ) has reported updates from a Phase I/II clinical trial...